Risperdal Attorneys at Bernstein Liebhard Note New Study Finding Risk...
The study’s publication comes as hundreds of people pursue Risperdal lawsuits for complications allegedly associated with the drug, including gynecomastia (male breast growth).(PRWeb January 13, 2015)Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-male-breasts/prweb12441513.htm
Publication date: Available online 11 May 2020Source: Academic RadiologyAuthor(s): Mohamad Ali Kazemi, Samira Hemmati, Behnaz Moradi, Hashem Sharifian, Kavous Firooznia, Nasrin Nikravangolsefid
In this study, we describe two male siblings with mild intellectual disability, global developmental delay, short stature, microcephaly, and nyctalopia. Whole exome sequencing of the affected siblings and the parents identified a missense var iant (c.413C > G) in thePHF6 gene, which leads to alteration of a serine residue at position 138 to cysteine. This mutation is located in a highly conserved region. Sanger sequencing confirmed the segregation of this mutation in the family in an X-linked recessive fashion. Multiple mass spectrometry-based proteomic studies have reported phosphorylation at serine 138 ...
We report a case that occurred in the breasts of a 62-year-old man. A clinical diagnosis of gynecomastia was initially made. Partial mastectomy was done and MSL was reported on histopathologic examination. Our literature search revealed no previous case of MSL in the breast reported from our environment.
In conclusion, immunoglobulins exhibit limited benefit on immune ‐neuropathy in patients with coexisting KD.
Conditions: Gynecomastia; Delayed Wound Healing Interventions: Drug: Nitroglycerin Paste; Drug: Dermabond Sponsor: Icahn School of Medicine at Mount Sinai Recruiting
Conclusions: Combining PBRT, PLNRT, and LT-ADT had an acceptable PFS in patients with significant post-operative risk factors for recurrence. While therapy was well-tolerated, long-term hypogonadism was a substantial risk. Further investigations are needed to determine if this combination is beneficial.Trial registration: NCT01255891.
ConclusionsProphylactic RT as well as daily TMX can significantly reduce the incidence of gynecomastia and/or breast pain. TMX appears to be an effective alternative to RT also as a therapeutic treatment in the presence of gynecomastia but its side effects and off-label use must be considered.